RevOpsis Therapeutics isn’t just another biotech chasing eye disease; it is a company that saw the cracks in the market and decided to build a new foundation. Founded in 2018 by Ram Bhandari, MD, FASRS, and Jeff Olson, MD, RevOpsis Therapeutics is headquartered in San Carlos, California, and is focused on a singular problem: most retinal patients aren’t getting the outcomes they need. Nearly 200 million people worldwide live with age-related macular degeneration, and in the U.S. alone the number sits at 11 million. Of those, 80-90% of severe vision loss stems from the neovascular form. Current VEGF-A therapies may be a $9 billion market, but about 70% of patients get subpar results. That failure rate is the opportunity RevOpsis Therapeutics is built around.
The company’s response is the RevMod Platform, a modular system that pieces together multispecific biologics from a library of roughly 30 billion fully human antibody components. Their lead asset, RO-104, is the first fully human tri-specific biologic engineered to simultaneously target VEGF-A, VEGF-C, and Ang-2. This approach delivers pan-VEGF blockade while shutting down Ang-2, aiming to finally move the needle for patients who have been underserved. RO-104 began IND-enabling studies in January 2025 and is slated for first-in-human trials late this year.
ExSight Ventures recognized that trajectory and on September 16, 2025, announced an undisclosed investment in RevOpsis Therapeutics. For a firm focused solely on ophthalmology innovation, this is more than a financial stake; it is a signal. Add it to a stack that already includes a $16.5 million seed round, nearly $8 million in convertible notes, and a $1.8 million NEI SBIR grant, and the company has now raised over $25 million to fuel its ambitions.
Partnerships and infrastructure matter just as much as capital. RevOpsis Therapeutics secured Kemwell Biopharma to provide GMP manufacturing, while a licensing deal with Asimov brought in the CHO Edge System with AI-driven biophysics and hyperactive transposase capabilities. That infrastructure turns ideas into clinical candidates.
The leadership team gives investors confidence this science will scale. Ram Bhandari serves as CEO and board chair, while Jeff Olson brings academic depth from the University of Colorado. Chief Scientific Officer Ramesh Bhatt, PhD, sharpened his craft at Protagonist and Janux. Chief Business Officer Ronil Patel has the industry network to strike the right deals. Li Xu, PhD, VP of Discovery, brings decades in protein engineering. The board includes heavy hitters like Ram Palanki, PharmD, and Kemwell Biopharma CEO Anurag Bagaria, MBA. Scientific advisors such as Peter K. Kaiser, MD, Jeff Heier, MD, and Arshad M. Khanani, MD keep the science grounded in clinical realities.
RevOpsis Therapeutics is a reminder that funding is not the finish line; it is the green light. With ExSight Ventures now in their corner, the company has the capital, the partners, and the team to test whether modular biology can finally outpace the complexity of retinal disease. For the patients who have been living with compromised vision and compromised treatments, that’s a shot worth taking.
